This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Cepheid (CPHD)

NASDAQ: Technology

11/30/15 - 3:59:00 PM ET
  • Prev Close: 35.94
  • Avg Vol: 1.16M
  • Shares Outstanding: 72.34M
  • Mkt Cap: 2.69B
  • Div: --
  • Div Yield: --
  • P/E: N/A
  • EPS: -0.72
CPHD Day's Range
CPHD 52 Week Range
CPHD Business Summary
Cepheid, a molecular diagnostics company, develops, manufactures, and markets integrated systems for testing in the clinical market and non-clinical markets. Its systems enable molecular testing for organisms and genetic-based diseases by automating manual laboratory procedures.View CPHD key stats
Cepheid - CPHD - EQUITY
Reviewed By: TheStreet Ratings on .
Report Summary: TheStreet Ratings team rates Cepheid as a Sell with a ratings score of D.
Report Snippet: We rate CEPHEID INC (CPHD) a SELL. This is driven by a few notable weaknesses, which we believe should have a greater impact than any strengths, and could make it more difficult for investors to achieve positive results compared to most of the stocks we cover. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, disappointing return on equity, weak operating cash flow and generally disappointing historical performance in the stock itself.
Rating: 2.00 out of 5, 'D' Sell.
You can view the full analysis from the report here:
CPHD Rating Report
CPHD Performance as of Prev. Close
CPHD EPS Performance
1-Yr Ago
2-Yrs Ago
3-Yrs Ago
CPHD Percentage in these ETFs

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free

Analysts Ratings for CPHD

Rating Current 1-Mo Ago 2-Mo Ago 3-Mo Ago
Strong Buy 12 10 10 10
Moderate Buy 0 0 2 2
Hold 5 6 4 3
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0

CPHD Chatter

Top Rated Stocks Top Rated Funds Top Rated ETFs